Rare accessory digestive gland diseases comprise a group of uncommon conditions that impact glands assisting in digestion but lie outside the main digestive tract. Due to their rarity and complexity, these diseases present unique challenges in diagnosis and therapeutic. Our company is a prominent provider of specialized disease research services and offers a wide array of tailored services to meet the distinct requirements of researchers and scientists working in this specialized domain.
Accessory organs are essential for digestive functions and exist distinct from the main digestive tract, and the liver, gallbladder, and pancreas fall under the category of accessory digestive glands. The organs secrete vital substances crucial for the chemical breakdown of food. The rare accessory digestive gland diseases encompass rare disorders like chronic granulomatous disease, primary sclerosing cholangitis, pancreatic pseudocyst, and more.
Fig.1 Contributing factors to EPI. (Radlinger, B., et al., 2020)The pathogenesis of rare accessory digestive gland diseases is intricate and influenced by multiple factors. Genetic mutations, autoimmune processes, developmental anomalies, inflammatory reactions, or structural irregularities within these glands can contribute to the initiation and progression of these disorders. For instance, in non-alcoholic steatohepatitis, issues with lipid metabolism in hepatocytes due to genetic factors, diet, and insulin resistance lead to lipid accumulation.
Fig.2 Progression of inflammation and fibrosis in the liver. (Lee, K. C., et al., 2023)Therapeutics development for accessory digestive gland diseases varies depending on the specific condition and its severity. Here are some therapeutics for diseases affecting accessory digestive glands like the liver, pancreas, gallbladder, and others.
| Diseases | Drug Names | Mechanism of Action | Targets | Research Phase |
| Exocrine Pancreatic Insufficiency (EPI) | Pertzye | Simulate normal pancreatic digestive function | Pancreatic enzyme replacement | Approved |
| Non-alcoholic steatohepatitis (NASH) | Aldafermin | Inhibition of bile acids synthesis and hepatic gluconeogenesis | FGF-19 | Phase II |
| Primary Sclerosing Cholangitis (PSC) | Bezafibrate | PPARα agonist | PPARα | Phase II |
| Fecal microbiota transfer | Transfer of healthy donor fecal microbiota to the gastrointestinal tract of a recipient to restore a healthy microbial balance | Dysbiosis | Phase I/II |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Our team consists of experts with extensive proficiency in rare accessory digestive gland diseases. Equipped with state-of-the-art technology, our modern facilities support cutting-edge research and experimentation. Through our diagnostic, therapeutic, and disease model development platforms, we provide a comprehensive solution for researchers and scientists to drive innovation and progress in the drug development field of rare accessory digestive gland diseases.
Types of Accessory Digestive Gland Diseases
Therapeutic and Animal Model Development Services
Furthermore, we offer comprehensive preclinical services for drug development for rare diseases, including pharmacokinetic studies and drug safety evaluations. Committed to fostering disease research endeavors, facilitating breakthrough discoveries in therapeutics, and furthering the comprehension and therapeutic of rare accessory digestive gland diseases.
If you are interested in our services, we invite you to contact us for more information on our services.
References
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.